Article
Association of the CYP1B1*3 allele with survival in patients with prostate cancer receiving docetaxel.
Molecular cancer therapeutics - 1 Jan 2008
Sissung Tristan M, Danesi Romano, Price Douglas K, Steinberg Seth M, de Wit Ronald, Zahid Muhammad, Gaikwad Nilesh, Cavalieri Ercole, Dahut William L, Sackett Dan L, Figg William D, Sparreboom Alex
Abstract excerpt
Using a single nucleotide polymorphism association study in 52 men with prostate cancer receiving docetaxel, we found that individuals carrying two copies of the CYP1B1*3 polymorphic variant had a poor prognosis after docetaxel-based therapies compared with individuals carrying at least one copy of the CYP1B1*1 allele (30.6 versus 12.8 months; P=0.0004). The association between CYP1B1*3 and response to therapy...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.